Does Dr. KARI CASAS have financial conflicts of interest?

Dr. KARI CASAS (MD) has received a total of $575 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $575 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. KARI CASAS?

According to CMS Open Payments data, Dr. KARI CASAS received funding from BIOMARIN PHARMACEUTICAL ($375), SPRINGWORKS THERAPEUTICS ($80), and ULTRAGENYX PHARMACEUTICAL ($60).

Does Dr. KARI CASAS receive research grants or speaking fees?

Dr. KARI CASAS has received $575 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. KARI CASAS

MDReal-Time Hydrated

Specialty: Medical Genetics, Clinical Genetics (M.D.)

Practice Location: FARGO, ND 58102

NPI Number: 1497723662

LIFETIME INDUSTRY VALUE

$575

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. CASAS is a verified Medical Genetics, Clinical Genetics (M.D.) practitioner based in FARGO, ND.

Between 2021 and 2025, Dr. CASAS had an overall industry promotional and research financial footprint of $575 as recorded in the federal CMS Open Payments database.

$575 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. CASAS's primary funding source is BIOMARIN PHARMACEUTICAL, which accounts for $375 (representing 65.3% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

BIOMARIN PHARMACEUTICAL

Rank 1

$375

65.3%

SPRINGWORKS THERAPEUTICS

Rank 2

$80

13.8%

ULTRAGENYX PHARMACEUTICAL

Rank 3

$60

10.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.